Published in J Clin Microbiol on April 01, 2001
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis (2005) 2.86
Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol (2008) 1.96
Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A (2005) 1.79
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2009) 1.73
Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS (2004) 1.65
Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther (2008) 1.58
Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol (2012) 1.48
Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. PLoS One (2010) 1.46
Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis (2012) 1.43
Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. J Infect Dis (2003) 1.42
Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS One (2011) 1.42
HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS (2006) 1.40
HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr (2003) 1.38
Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J Virol (2004) 1.34
Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance. J Clin Microbiol (2003) 1.25
Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob Agents Chemother (2002) 1.20
TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods (2009) 1.06
Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. J Clin Microbiol (2003) 1.04
Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants. J Clin Microbiol (2005) 1.03
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq Compend (2001) 0.98
Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays. J Clin Microbiol (2005) 0.93
Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis. BMC Infect Dis (2013) 0.91
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res Hum Retroviruses (2006) 0.88
Evaluation of a cost effective in-house method for HIV-1 drug resistance genotyping using plasma samples. PLoS One (2014) 0.87
Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients. J Virol (2007) 0.85
HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. J Acquir Immune Defic Syndr (2006) 0.85
The Brazilian network for HIV-1 genotyping external quality control assurance programme. J Int AIDS Soc (2011) 0.84
Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. ACS Chem Biol (2012) 0.82
A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation. PLoS One (2014) 0.80
More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1. Elife (2016) 0.79
Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance. Viruses (2012) 0.77
Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplification. J Clin Microbiol (2005) 0.77
Use of the l1 norm for selection of sparse parameter sets that accurately predict drug response phenotype from viral genetic sequences. AMIA Annu Symp Proc (2005) 0.75
Reverse transcriptase and protease sequence evolution in two HIV-1-infected couples. J Acquir Immune Defic Syndr (2002) 0.75
Avoiding false positives with PCR. Nature (1989) 30.66
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 5.64
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet (1999) 4.68
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection. HIV Clin Trials (2001) 4.51
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther (2000) 3.14
Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature (1993) 2.86
Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68
Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol (1999) 2.63
Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses (1998) 2.50
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J Clin Microbiol (1997) 1.74
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS (1999) 1.65
Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res (2000) 1.58
Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. J Virol Methods (1998) 1.41
Retrovirus mutation rates and their role in genetic variation. J Gen Virol (1998) 1.39
Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay. J Clin Microbiol (2000) 1.38
Peak height pattern in dichloro-rhodamine and energy transfer dye terminator sequencing. Biotechniques (1998) 1.17
Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals. J Virol Methods (2000) 1.02
Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol (2000) 1.02
Principles of HIV resistance testing and overview of assay performance characteristics. Antivir Ther (2000) 0.98
Limits of resistance testing. Antivir Ther (2000) 0.89
Clinical utility of testing human immunodeficiency virus for drug resistance. Clin Infect Dis (2000) 0.85
Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (2001) 8.89
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 8.86
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 8.76
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A (1993) 6.14
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 5.64
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A (1992) 5.19
Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature (1987) 4.45
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol (1983) 4.09
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N Engl J Med (1983) 3.83
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med (1998) 3.55
Related functional domains in virus DNA polymerases. EMBO J (1987) 3.35
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol (1991) 3.32
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Concerning the mechanism of action of interferon. Proc Natl Acad Sci U S A (1966) 3.15
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther (2000) 3.14
Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (1994) 3.07
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol (2001) 3.05
Inhibition of respiratory virus infection by locally applied interferon. Lancet (1973) 3.02
Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med (2000) 2.99
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
On-line computer quality control of antibiotic-sensitivity testing. N Engl J Med (1970) 2.88
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med (1976) 2.80
Inhibition of TRIC agents by virus-induced interferon. Proc Soc Exp Biol Med (1966) 2.78
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
Physical properties of human interferon prepared in vitro and in vivo. Virology (1966) 2.62
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol (1999) 2.51
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol (1998) 2.50
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 2.50
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci U S A (1984) 2.32
Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus. J Infect Dis (1982) 2.29
Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest (1985) 2.28
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 2.28
Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol (1994) 2.18
Interferon inducers in vitro: difference in sensitivity to inhbitiros of RNA and protein synthesis. Science (1968) 2.16
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS (2000) 2.15
Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology (1988) 2.14
Cellular immunity and herpesvirus infections in cardiac-transplant patients. N Engl J Med (1977) 2.09
Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons. J Immunol (1975) 2.09
Measles in adults. An unforeseen consequence of immunization? JAMA (1976) 2.08
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother (1999) 2.08
Patient compliance and drug failure in protease inhibitor monotherapy. JAMA (1996) 2.06
Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med (1978) 2.04
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol (1996) 2.03
Interferon-stimulating and in vivo antiviral effects of various synthetic anionic polymers. Virology (1968) 1.96
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92
Synthetic polyanions protect mice against intracellular bacterial infection. Nature (1970) 1.92
Tuberculosis prophylaxis in the homeless. A trial to improve adherence to referral. Arch Intern Med (1996) 1.92
Induction of circulating interferon by synthetic anionic polymers of known composition. Nature (1967) 1.92
Interferon and cytomegalovirus in vivo and in vitro. Proc Soc Exp Biol Med (1967) 1.85
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest (1991) 1.85
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS (1999) 1.85
Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J Gen Virol (1991) 1.80
Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol (1995) 1.80
Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture. Antimicrob Agents Chemother (1994) 1.79
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis (1995) 1.79
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis (1995) 1.77
The interaction of human macrophages and lymphocytes in the phytohemagglutinin-stimulated production of interferon. J Clin Invest (1971) 1.75
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother (2000) 1.75
PPD-stimulated interferon: in vitro macrophage-lymphocyte interaction in the production of a mediator of cellular immunity. Cell Immunol (1971) 1.75
Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine. J Biol Chem (1992) 1.75
Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J Clin Microbiol (1997) 1.74
Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med (1973) 1.73
A useful quantitative semimicromethod for viral plaque assay. Proc Soc Exp Biol Med (1973) 1.73
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS (2001) 1.73
Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. Proc Natl Acad Sci U S A (1972) 1.73
Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. J Virol (1985) 1.73
An in vitro model of angiogenesis: basic features. Angiogenesis (1999) 1.71
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr (2001) 1.71
Viral infections in man associated with acquired immunological deficiency states. Fed Proc (1972) 1.70
Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. J Gen Virol (1986) 1.69
Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes. J Clin Microbiol (1995) 1.69
An artificial intelligence program to advise physicians regarding antimicrobial therapy. Comput Biomed Res (1973) 1.69
Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase. FEBS Lett (1991) 1.69
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS (1999) 1.68
A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol (1997) 1.68
Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus. Infect Immun (1976) 1.67
Interferon, antibody, and other host factors in herpes zoster. J Clin Invest (1972) 1.64
The immunosuppressive effect of type II mouse interferon preparations on antibody production. Cell Immunol (1977) 1.64